Guideline Central Blog

News

British Society for Rheumatology Int'l Guidelines

British Society for Rheumatology (BSR) – Guidelines International Series

In this edition of our Guidelines International Series, we delve into the British Society for Rheumatology (BSR), the foremost specialist medical society in the UK for rheumatology and musculoskeletal professionals dedicated to enhancing the quality of life for children and adults with rheumatic and musculoskeletal diseases. The BSR is well known for its comprehensive collection […]

Alirocumab (Praluent/Regeneron) – Guidelines+ Monographs

In this edition of the Guidelines+ Monographs Series will delve into the medication alirocumab, marketed under the brand name Praluent® from Regeneron. Praluent (alirocumab) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, as […]

Guidelines+ Trials Spotlight - (Tecvayli) for Patients with Newly Diagnosed Multiple Myeloma

Tecvayli Clinical Trial Results for Patients With Newly Diagnosed Multiple Myeloma – Guidelines+ Trials Spotlight

On October 25, 2022, the US Food and Drug Administration (FDA) granted approval for Johnson & Johnson’s Tecvayli® (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma. This approval is specifically for patients who have previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and […]

Irinotecan Liposome Injection (Onivide/Ipsen) – Guidelines+ Monographs

Our latest edition of the Guidelines+ Monographs Series will delve into the medication irinotecan liposome injection, marketed under the brand name Onivyde®  by Ipsen. Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan used in the treatment of pancreatic adenocarcinoma. Onivyde is indicated in combination with oxaliplatin, fluorouracil and leucovorin, […]

Guidelines+ Trials Spotlight - TROPION-Lung01 Phase III trial

EGFR-Mutated NSCLC (The TROPION-Lung01 Phase III Trial) – Guidelines+ Trials Spotlight

AstraZeneca and Daiichi Sankyo have collaboratively submitted a new Biologics License Application (BLA) for accelerated approval in the United States for datopotamab deruxtecan (Dato-DXd). This application aims to provide treatment for adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have previously undergone systemic therapies, including […]

ASH 2024 Conference Recap - Bleeding & Clotting Disorders

2024 ASH Annual Meeting and Exposition – Conference Recap on Bleeding & Clotting Disorders

The 66th ASH Annual Meeting and Exposition took place from December 7-10, 2024, in San Diego, California, as well as online. This event is the premier hematology gathering of the year, attracting over 30,000 health professionals, clinicians, researchers, educators, and other industry experts. Attendees can expect a multitude of sessions, thousands of abstracts, and numerous […]

Guidelines Spotlight Diagnosis & Management of Myocarditis

ACC’s Guidance for the Diagnosis & Management of Myocarditis – Guidelines Spotlight

The American College of Cardiology (ACC) has recently released guidance for diagnosing and treating acute myocarditis in adult patients. The 2024 ACC Expert Consensus Decision Pathway (ECDP) on Strategies and Criteria for the Diagnosis and Management of Myocarditis outlines a 5-step care pathway, along with recommendations for resuming strenuous physical activity. Additionally, the guidelines aim […]

Guideline Timeline - Restless Leg Syndrome

Restless Leg Syndrome – Guidelines Timeline

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, primary RLS, and idiopathic RLS, is a neurological disorder characterized by unpleasant sensations in the legs and an irresistible urge to move them. The Centers for Disease Control (CDC) estimates that up to 7-10% of the US population may be affected by RLS, with onset possible […]

Guidelines Spotlight Diabetes Standards of Care (2025)

Diabetes Standards of Care (2025) – Guidelines Spotlight

Welcome to the latest edition of our Guideline Spotlight, where we will explore the valuable insights and key takeaways from the most recent guideline releases. Today, our focus is on the American Diabetes Association’s (ADA) latest edition of their Standards of Care in Diabetes, which was released on December 9, 2024. This edition consolidates all […]

AUA Seeks Peer Reviewers for Upcoming Vasectomy Guideline

The American Urological Association (AUA) is currently seeking feedback and comments on their draft vasectomy guideline. AUA members and other interested parties will have the opportunity to review the draft guideline starting in January 2025, for a period of approximately two weeks. Prior to receiving a copy of the draft guideline, all reviewers must disclose […]

USPSTF’s Cervical Cancer Screening Recommendation is Now Open for Public Comment

The United States Preventive Services Task Force (USPSTF) recently released their draft recommendation statement titled Cervical Cancer: Screening, which was published online on December 10, 2024. This recommendation serves as an update to the previous 2018 guideline. The latest draft remains consistent with the 2018 recommendation but includes a new recommendation. It now suggests that […]

Guidelines+ Trials Spotlight - Metastatic Squamous Cell Carcinoma of the Head & Neck (STELLAR-305)

Metastatic Squamous Cell Carcinoma of the Head and Neck (STELLAR-305) – Guidelines+ Trials Spotlight

One year ago, Exelixis commenced their phase 2/3 pivotal trial to assess the efficacy of zanzalintinib in combination with pembrolizumab compared to pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Zanzalintinib, an oral drug developed by Exelixis, targets and inhibits receptor tyrosine kinases […]

Baloxavir Marboxil (Xofluza/Genetech) – Guidelines+ Monographs

In recognition of National Influenza Vaccination Week (NIVW), our latest edition of the Guidelines+ Monographs Series will delve into the medication baloxavir marboxil, marketed under the brand name Xofluza®  by Genentech. Xofluza is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 5 years of age […]

CDC’s HIV Screening Guideline is Now Open for Public Comment

The US Centers for Disease Control and Prevention (CDC) has released the latest draft of the Recommendations for HIV Screening in Clinical Settings for public comment. This guideline aims to aid healthcare providers in diagnosing and connecting patients with undiagnosed HIV to clinical care, reestablishing individuals with previously diagnosed HIV in care, detecting HIV infection […]

Guideline Timeline - Influenza Vaccine Recommendations

Influenza Vaccine Recommendations – Guidelines Timeline (National Influenza Vaccination Week)

National Influenza Vaccination Week (NIVW) is a national awareness week dedicated to emphasizing the significance of influenza vaccination. Taking place from December 2-6, 2024, National Influenza Vaccination Week 2024 serves as a timely reminder for individuals aged 6 months and older that there is still an opportunity to receive a flu vaccine this season. Given […]

Guidelines Spotlight HIVAIDS

Human Immunodeficiency Virus (HIV) Guidelines Spotlight – (World AIDS Day)

World AIDS Day is observed annually on December 1st, providing a global platform for individuals to come together in solidarity with those affected by HIV and to honor those who have succumbed to AIDS-related illnesses. Each year, World AIDS Day centers around a specific theme, with this year’s focus being on “Taking the Rights Path.” […]

Bictegravir, Emtricitabine, and Tenofovir Alafenamide (Biktarvy/Gilead ) – Guidelines+ Monographs

In recognition of World AIDS Day 2024, our latest edition of the Guidelines+ Monographs Series will delve into the medication bictegravir, emtricitabine, and tenofovir alafenamide, marketed under the brand name Biktarvy®  by Gilead Sciences, Inc. Biktarvy is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), […]

Guidelines Spotlight Management of Central Airway Obstruction

Management of Central Airway Obstruction – Guidelines Spotlight  (COPD Awareness Month)

Welcome to this edition of our Guideline Spotlight, where we will delve into the important insights and key takeaways from the comprehensive guideline on the Management of Central Airway Obstruction, developed by The American College of Chest Physicians (CHEST). Central airway obstruction (CAO) is a critical condition that poses a significant threat to life, leading […]

Upcoming FDA Approvals & Decisions - December 2024

Upcoming FDA Decisions – December 2024

The Food and Drug Administration (FDA) protects public health by guaranteeing the safety, effectiveness, and security of pharmaceuticals and medical devices. The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the FDA must complete its review of drug applications. Occasionally, an advisory committee (AdCom) meeting is convened to assess the drug […]

ASH 2024 Conference Preview - Bleeding & Clotting Disorders

2024 ASH Annual Meeting and Exposition – Conference Preview on Bleeding & Clotting Disorders

The 66th ASH Annual Meeting and Exposition is set to take place from December 7-10, 2024, in San Diego, California, as well as online. This event stands as the premier hematology gathering of the year, attracting over 30,000 health professionals, clinicians, researchers, educators, and other industry experts. Attendees can expect a multitude of sessions, thousands […]

Guideline Spotlight - Adult Vaccination Schedule

CDC Adult Vaccination Schedule (2025) – Guidelines Spotlight 

Welcome to the latest edition of our Guideline Spotlight, where we delve into the significant changes and key takeaways from the Centers for Disease Control and Prevention’s (CDC) Adult Immunization Schedule for Ages 19 Years or Older, United States, 2025. This schedule serves as a valuable tool for healthcare providers to determine the recommended vaccines […]

Guideline Spotlight - Childhood & Adolescents Vaccination Schedule

CDC Childhood and Adolescent Vaccination Schedule (2025) – Guidelines Spotlight 

In this edition of our Guideline Spotlight, where we take a look into the significant changes and key takeaways from the Centers for Disease Control and Prevention’s (CDC) Recommended Childhood and Adolescent Immunization Schedule: United States, 2025. This schedule serves as a valuable tool for healthcare providers to determine the recommended vaccines for individuals within […]

ACR 2024 Recap

ACR Convergence 2024 – Conference Recap on Gout

The American College of Rheumatology’s annual meeting, ACR Convergence 2024, was held from November 14 to 19 at the Walter E. Washington Convention Center in Washington, D.C. This prestigious event brought together leading experts in the field to exchange the latest advancements in rheumatology. At ACR Convergence 2024, several significant abstracts were presented focusing on […]